DUBLIN--(BUSINESS WIRE)--The "IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering Technology, Application - Global Forecast to 2031" report has been added to ...

LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ...

On April 29, 2023, the FDA announced a final rule on regulation of laboratory developed tests (LDTs).[1] The rule explicitly categorizes in vitro diagnostic products (IVDs) intended for clinical use ...

Register for our upcoming webinar “Accelerate your IVD assay development with the unique support of the Dynabeads team” and learn how Dynabeads technology and commercial partnership can help ...

The Centers for Medicare and Medicaid Services’ (CMS) recent move to finalize a national coverage determination (NCD) for next generation sequencing (NGS) cancer panels underscores an emerging trend ...

The current European legislation for in vitro diagnostic medical devices (IVD) (Regulation 2017/746 or the IVDR) has created challenges not only for IVD manufacturers but also for pharmaceutical ...

This course provides a basic overview of IVDs, including an historical background focused on regulatory requirements. It introduces key regulations and guidelines necessary for effective product ...

GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic ...

As the diagnostic industry evolves under new regulations and advancing technologies, outsourcing production has become vital to maintain innovation and speed. Yet, identifying the right manufacturing ...

LONDON, April 14, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immunology research and diagnostics, today ...

Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic ("IVD") development and ...